Featured Studies Results
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
https://www.facingourrisk.org/research-clinical-trials/study/413 /the-ease-study-helping-people-with-advanced-cancer-cope-with-fear-of-cancer-progression
Clinicaltrials.gov identifier:
NCT07636200 (https://clinicaltrials.gov/show/NCT07636200)
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
Perceptions of Gastric Cancer Risk and Attitudes Toward Endoscopic Surveillance in People with CDH1 or CTNNA1 Mutations
https://www.facingourrisk.org/research-clinical-trials/study/390 /perceptions-of-gastric-cancer-risk-and-attitudes-toward-endoscopic-surveillance-in-people-with-cdh1-or-ctnna1-mutations
Surveys, Registries, Interviews
Online survey about gastric cancer risk and medical decision-making for people with an inherited CDH1 or CTNNA1 pathogenic variant
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
https://www.facingourrisk.org/research-clinical-trials/study/409 /treating-advanced-solid-tumors-with-a-kras-g12c-mutation-using-targeted-therapies-called-rason-inhibitors
Clinicaltrials.gov identifier:
NCT06128551 (https://clinicaltrials.gov/show/NCT06128551)
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer
Clinicaltrials.gov identifier:
NCT06411691 (https://clinicaltrials.gov/show/NCT06411691)
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)
https://www.facingourrisk.org/research-clinical-trials/study/404 /
Clinicaltrials.gov identifier:
NCT04294927 (https://clinicaltrials.gov/show/NCT04294927)
Prevention
Prevention study for women at high risk for ovarian cancer
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
https://www.facingourrisk.org/research-clinical-trials/study/388 /comparing-hormone-therapy-with-and-without-chemotherapy-for-premenopausal-breast-cancer-ofset
Clinicaltrials.gov identifier:
NCT05879926 (https://clinicaltrials.gov/show/NCT05879926)
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab
https://www.facingourrisk.org/research-clinical-trials/study/362 /testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)
Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/353 /using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)
Prevention
Screening for people at high risk for prostate cancer
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/360 /the-prostate-cancer-genetic-risk-and-equitable-screening-study-progress
Clinicaltrials.gov identifier:
NCT05926102 (https://clinicaltrials.gov/show/NCT05926102)
Prevention
Prostate cancer screening study for male US veterans age 55–69
Understanding Access to Genetic Services for Latina Women with Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/367 /understanding-access-to-genetic-services-for-latina-women-with-breast-cancer
Surveys, Registries, Interviews
A phone survey for Latina breast cancer survivors diagnosed within the past five years in California
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2
Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)
Treatment
Phase 1 treatment study for metastatic solid tumors
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/358 /post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer
Clinicaltrials.gov identifier:
NCT07140679 (https://clinicaltrials.gov/show/NCT07140679)
Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD
https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)
https://www.facingourrisk.org/research-clinical-trials/study/347 /testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT06958328 (https://clinicaltrials.gov/show/NCT06958328)
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)
https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer
Clinicaltrials.gov identifier:
NCT06952803 (https://clinicaltrials.gov/show/NCT06952803)
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.